• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    2/14/23 4:17:23 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RPID alert in real time by email
    SC 13G/A 1 d442607dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Rapid Micro Biosystems, Inc.

    (Name of Issuer)

    Class A Common Stock, $0.01 par value per share

    (Title of Class of Securities)

    75340L104

    (CUSIP Number)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    13G

    CUSIP No. 75340L104

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Longitude Capital Partners II, LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      4,039,845 (1)(2)

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      4,039,845 (1)(2)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,039,845 (1)(2)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      10.9% (3)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      OO

     

    (1)

    All such shares are held of record by LVPII (as defined in the Explanatory Note below). LCPII (as defined in the Explanatory Note below) is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (a) 3,407,952 outstanding shares of Class A Common Stock, and (b) 631,893 shares of Common Stock issuable upon exercise of Class A Common Stock Warrants (“Warrants”).

    (3)

    Based on 37,072,799 shares of Class A Common Stock, as follows: (a) 36,440,906 shares of Class A Common Stock outstanding as of November 7, 2022 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the “Commission”) on November 10, 2022 (the “Form 10-Q”) plus (b) 631,893 shares of Class A Common Stock issuable upon exercise of the Warrants held of record by LVPII.


    13G

    CUSIP No. 75340L104

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Longitude Venture Partners II, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      4,039,845 (1)(2)

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      4,039,845 (1)(2)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,039,845 (1)(2)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      10.9% (3)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    All such shares are held of record by LVPII. LCPII is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (a) 3,407,952 outstanding shares of Class A Common Stock, and (b) 631,893 shares of Class A Common Stock issuable upon exercise of the Warrants held of record by LVPII.

    (3)

    Based on 37,072,799 shares of Class A Common Stock, as follows: (a) 36,440,906 shares of Class A Common Stock outstanding as of November 7, 2022 as reported by the Issuer in the Form 10-Q, plus (b) 631,893 shares of Class A Common Stock issuable upon exercise of the Warrants held of record by LVPII.


    13G

    CUSIP No. 75340L104

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Longitude Prime Partners, LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      150,000 (1)

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      150,000 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      150,000 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.4% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      OO

     

    (1)

    All such shares are held of record by LPF (as defined in the Explanatory Note below). LPP (as defined the Explanatory Note below) is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 36,440,906 shares of Class A Common Stock outstanding as of November 7, 2022 as reported by the Issuer in the Form 10-Q.


    13G

    CUSIP No. 75340L104

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Longitude Prime Fund, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      150,000 (1)

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      150,000 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      150,000 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.4% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    All such shares are held of record by LPF. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 36,440,906 shares of Class A Common Stock outstanding as of November 7, 2022 as reported by the Issuer in the Form 10-Q.


    13G

    CUSIP No. 75340L104

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Patrick G. Enright

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      4,189,845 (1)(2)

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      4,189,845 (1)(2)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,189,845 (1)(2)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      11.3% (3)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      IN

     

    (1)

    All such securities are held of record by LVPII and LPF. LCPII is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to the shares held by LVPII. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Mr. Enright is a managing member of each of LCPII and LPP and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (a) 3,407,952 outstanding shares of Class A Common Stock held of record by LVPII, (b) 631,893 shares of Class A Common Stock issuable upon exercise of the Warrants held of record by LVPII and (c) 150,000 outstanding shares of Class A Common Stock held of record by LPF.

    (3)

    Based on 37,072,799 shares of Class A Common Stock, as follows: (a) 36,440,906 shares of Class A Common Stock outstanding as of November 7, 2022 as reported by the Issuer in the Form 10-Q, plus (b) 631,893 shares of Class A Common Stock issuable upon exercise of the Warrants held of record by LVPII.


    13G

    CUSIP No. 75340L104

     

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Juliet Tammenoms Bakker

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      4,189,845 (1)(2)

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      4,189,845 (1)(2)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,189,845 (2)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      11.3% (3)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      IN

     

    (1)

    All such securities are held of record by LVPII and LPF. LCPII is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to the shares held by LVPII. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Ms. Bakker is a managing member of each of LCPII and LPP and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (a) 3,407,952 outstanding shares of Class A Common Stock held of record by LVPII, (b) 631,893 shares of Class A Common Stock issuable upon exercise of the Warrants held of record by LVPII and (c) 150,000 outstanding shares of Class A Common Stock held of record by LPF.

    (3)

    Based on 37,072,799 shares of Class A Common Stock, as follows: (a) 36,440,906 shares of Class A Common Stock outstanding as of November 7, 2022 as reported by the Issuer in the Issuer’s Form 10-Q, plus (b) 631,893 shares of Class A Common Stock issuable upon exercise of the Warrants held of record by LVPII.


    13G

    CUSIP No. 75340L104

     

    Explanatory Note

    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Schedule 13G initially filed with the Commission on February 15, 2022 (the “Original Schedule 13G”) and is being filed by Longitude Capital Partners II, LLC (“LCPII”), Longitude Venture Partners II, L.P. (“LVPII”), Longitude Prime Partners, LLC (“LPP”) and Longitude Prime Fund, L.P. (“LPF” and together with LCPII, LVPII and LPP, the “Reporting Entities”) and Patrick G. Enright and Juliet Tammenoms Bakker (together, the “Reporting Individuals”). The Reporting Entities and the Reporting Individuals are collectively referred to as the “Reporting Persons.” The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is filed as Exhibit 1 to the Original Schedule 13G. David Hirsch, a reporting person on the Original Schedule 13D, is no longer a managing director of entities affiliated with LCPII, and accordingly, is not deemed to share voting, investment and dispositive power with respect to the securities held by the Reporting Entities. As such, David Hirsch is no longer a reporting person on this Amendment No. 1. The Original Schedule 13D is hereby amended to delete all references to David Hirsch. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Schedule 13G.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person.

    LVPII is the record owner of 3,407,952 shares of Class A Common Stock and 631,893 Class A Common Stock Warrants (collectively, the “LVPII Shares”). As general partner of LVPII, LCPII may be deemed to beneficially own the LVPII Shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting, investment and dispositive power with respect to the LVPII Shares. LPF is the record owner of 150,000 shares of Class A Common Stock (the “LPF Shares”). As general partner of LPF, LPP may be deemed to beneficially own the LPF Shares. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power with respect to the LPF Shares.

    (b) Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

    (ii) Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

    (iii) Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

    (iv) Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his, her or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Class A Common Stock, except for the shares, if any, such Reporting Person holds of record.


    13G

    CUSIP No. 75340L104

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2023.

     

    LONGITUDE CAPITAL PARTNERS II, LLC
    By:  

    /s/ Cristiana Blauth Oliveira

      Cristiana Blauth Oliveira
    Its:   Authorized Signatory
    LONGITUDE VENTURE PARTNERS II, L.P.
    By:   Longitude Capital Partners II, LLC
    Its:   General Partner
    By:  

    /s/ Cristiana Blauth Oliveira

      Cristiana Blauth Oliveira
    Its:   Authorized Signatory
    LONGITUDE PRIME PARTNERS, LLC
    By:  

    /s/ Cristiana Blauth Oliveira

      Cristiana Blauth Oliveira
    Its:   Authorized Signatory
    LONGITUDE PRIME FUND, L.P.
    By:   Longitude Prime Partners, LLC
    Its:   General Partner
    By:  

    /s/ Cristiana Blauth Oliveira

      Cristiana Blauth Oliveira
    Its:   Authorized Signatory

    /s/ Patrick G. Enright

    Patrick G. Enright

    /s/ Juliet Tammenoms Bakker

    Juliet Tammenoms Bakker
    Get the next $RPID alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPID

    DatePrice TargetRatingAnalyst
    2/12/2025$8.00Overweight
    KeyBanc Capital Markets
    8/16/2022Overweight → Neutral
    JP Morgan
    3/7/2022$11.00 → $10.00Equal-Weight
    Morgan Stanley
    2/15/2022$24.00 → $11.00Equal-Weight
    Morgan Stanley
    11/15/2021$26.00 → $24.00Equal-Weight
    Morgan Stanley
    8/9/2021Outperform
    Cowen
    8/9/2021$26.00Equal-Weight
    Morgan Stanley
    8/9/2021$28.00Buy
    Stifel
    More analyst ratings

    $RPID
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

      Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

      5/9/25 7:00:55 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

      LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after

      4/24/25 4:15:32 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units ("RSUs") of the Company's Class A common stock ("Common Stock") as a material inducement to employment of one new employee and (ii) on March 10, 2025, of non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the "Options") and 174,000 RSUs as a material inducement to employment to two

      3/12/25 4:30:02 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • KeyBanc Capital Markets initiated coverage on Rapid Micro Biosystems with a new price target

      KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00

      2/12/25 7:09:40 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems downgraded by JP Morgan

      JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral

      8/16/22 7:57:15 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley reiterated coverage on Rapid Micro Biosystems with a new price target

      Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously

      3/7/22 8:37:27 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $RPID
    Financials

    Live finance-specific insights

    See more

    $RPID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      2/14/24 10:04:40 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      1/22/24 5:28:26 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      2/14/23 4:17:23 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

      Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

      5/9/25 7:00:55 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

      LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after

      4/24/25 4:15:32 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

      Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023.Announces global Distribution and Collaboration Agreement with MilliporeSigma LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro

      2/28/25 6:30:13 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Pei Melinda Litherland bought $20,364 worth of shares (20,000 units at $1.02), increasing direct ownership by 58% to 54,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      12/5/24 6:44:47 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Pei Melinda Litherland bought $20,999 worth of shares (20,000 units at $1.05), increasing direct ownership by 140% to 34,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      11/27/24 9:42:03 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Malloy Kirk bought $45,335 worth of shares (50,000 units at $0.91), increasing direct ownership by 350% to 64,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      8/9/24 8:36:24 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Leadership Updates

    Live Leadership Updates

    See more
    • Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

      LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar

      7/18/23 5:20:56 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing

      LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S

      5/4/23 4:30:10 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Reaction Biology Announces Appointment of Richard S. Kollender to Chief Financial Officer and Chief Business Officer

      MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth. "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology.  "Having managed large, global biopharmaceut

      4/4/22 9:30:00 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    SEC Filings

    See more
    • SEC Form 10-Q filed by Rapid Micro Biosystems Inc.

      10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      5/9/25 4:21:23 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      5/9/25 7:06:07 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Rapid Micro Biosystems Inc.

      DEFA14A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      4/8/25 4:53:08 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Spignesi Robert G. Jr. covered exercise/tax liability with 10,650 shares, decreasing direct ownership by 1% to 872,366 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:19:38 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CHIEF FINANCIAL OFFICER Wirtjes Sean M covered exercise/tax liability with 7,690 shares, decreasing direct ownership by 2% to 489,955 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:18:44 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CHIEF OPERATING OFFICER Wilson John J. Addington covered exercise/tax liability with 9,872 shares, decreasing direct ownership by 4% to 232,474 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:17:20 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials